Auro Peptides Limited, a active public limited company, was established on 02 January 2012 in Hyderabad, Telangana, India. Engaging in drug formulation & development within the manufacturing sector, it holds CIN: U24232TG2012PLC078350. Registered under ROC Roc Hyderabad. it is unlisted. It has an authorized capital of ₹450.10 Cr and a paid-up capital of ₹336.10 Cr.
It upholds a compliant status. Employing 169 professional, Its leadership includes Sivakumaran Meenakshisunderam (Director), Chandra Reddy Tirumalareddy (Whole-Time Director), Satakarni Makkapati (Director). Past directors included Vinod Kumar Reddy Aerva, Singhal Shilpa, Govindarajan Narayanan. Its latest AGM occurred on 01 September 2025, with the balance sheet filed on 31 March 2025. It is based at Galaxy, Floors 22-24, Plot No. 1, Survey No. 83/1 Hyderabad Knowledge City, Raidurg Panmak, Tha, Hyderabad, Telangana, 500032.
U24232TG2012PLC078350
078350
02 January 2012
₹450.10 Cr
₹336.10 Cr
Roc Hyderabad
Unlisted
Active
Explore comprehensive insights into Auro Peptides Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Sivakumaran Meenakshisunderam | Director | 29 Sep 2017 | Current |
| Chandra Reddy Tirumalareddy | Whole-Time Director | 23 May 2019 | Current |
| Satakarni Makkapati | Director | 02 Nov 2021 | Current |
| Naga Venkata Subbarao Kesavarapu | Director | 20 Jan 2023 | Current |
| Rajendra Rekapu Krishna | Additional Director | 30 Oct 2025 | Current |
| Mylandlahalli Rammohan Ashwini | Additional Director | 30 Oct 2025 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Director | 15 Jun 2022 | Past |
| Pramod Abcsdd | Director | 10 Nov 2022 | Past |
| Pramod Abcsdd | Director | 29 Sep 2017 | Past |
| Pramod Abcsdd | Director | 02 Nov 2021 | Past |
| Pramod Abcsdd | Additional Director | 27 Aug 2018 | Past |
| Pramod Abcsdd | Additional Director | 20 Jun 2022 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Auro Peptides Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 141.42% increase. The company also saw a substantial improvement in profitability, with a 58.63% increase in profit. The company's net worth observed a substantial decline by a decrease of 10.32%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2023, Auro Peptides had a promoter holding of 95.00% and a public holding of 5.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
There are no open charges registered against the company as per our records.
Auro Peptides has a workforce of 169 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Auro Peptides, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Auro Peptides's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
The activity Ravi Kiran Yellapragada was appointed as a Cfo was appointed as a Cfo on 19 Nov 2025 & has been associated with this company since 9 days . was completed.
Rajendra Rekapu Krishna was appointed as a Additional Director was appointed as a Additional Director on 30 Oct 2025 & has been associated with this company since 29 days . was recorded as a recent event.
Progress on Mylandlahalli Rammohan Ashwini was appointed as a Additional Director was appointed as a Additional Director on 30 Oct 2025 & has been associated with this company since 29 days . was documented.
Progress on Auro Peptides Limited last Annual general meeting of members was held on 01 Sep 2025 as per latest MCA records. was documented.
Progress on Auro Peptides Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Hyderabad. was documented.
The activity Kadapa Gandla Sunanda was appointed as a Company Secretary was appointed as a Company Secretary on 27 Aug 2024 & has been associated with this company since 1 year 3 months . was completed.
FDA: Aurobindo Pharma's manufacturing facility has incomplete and misleading documents. They also found issues with quality control and training. Equipment is not cleaned properly. Aurobindo says they will fix it. FDA inspected from Sept 19-27 and issued warning letter for other facility. Aurobindo's stock went down..
The CIN of Auro Peptides Limited is U24232TG2012PLC078350.
Auro Peptides Limited is headquartered at Galaxy, Floors 22-24, Plot No. 1, Survey No. 83/1 Hyderabad Knowledge City, Raidurg Panmak, Tha, Hyderabad, Telangana, 500032.
Auro Peptides Limited was incorporated on 02 January 2012.
The current directors of Auro Peptides Limited are
The primary industry of Auro Peptides Limited is Manufacturing.
Auro Peptides Limited is unlisted.
The authorized capital of Auro Peptides Limited is ₹450.10 Cr, and the paid-up capital is ₹336.10 Cr.
The compliance status of Auro Peptides Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX